Publications by authors named "Yongwei Jing"
Recent advances in cancer therapy have underscored the importance of targeting specific metabolic pathways. In this study, we propose a precision nutrition approach aimed at lysosomal function in glioblastoma multiforme (GBM). Using patient-derived GBM cells, we identify lysosomal activity as a unique metabolic biomarker of tumorigenesis, controlling the efficacy of temozolomide (TMZ), a standard GBM therapy.
View Article and Find Full Text PDFArticle Synopsis
- Differentiation therapy shows potential for treating acute myeloid leukemia (AML), but effective methods that work across different AML subtypes are needed.
- The study reveals that inhibiting a specific regulatory element of FOXO genes can induce differentiation in AML cells, identifying TRIB1 as a key gene that keeps these cells undifferentiated.
- A new therapeutic approach combining a DNA-binding inhibitor with a chemotherapy drug effectively reduced TRIB1 levels, leading to AML cell differentiation and inhibiting tumor growth in animal models without significant side effects.
Lysosomes function as the digestive system of a cell and are involved in macromolecular recycling, vesicle trafficking, metabolic reprogramming, and progrowth signaling. Although quality control of lysosome biogenesis is thought to be a potential target for cancer therapy, practical strategies have not been established. Here, we show that lysosomal membrane integrity supported by lysophagy, a selective autophagy for damaged lysosomes, is a promising therapeutic target for glioblastoma (GBM).
View Article and Find Full Text PDF